Figure 5

Lipocalin 2 promotes breast cancer cell migration through suppressing PI3K/Akt pathway. (A) Upper panels: the expression and activation of Akt detected by immunoblotting with anti-Akt, anti-p-Akt Ser (473), and anti-p-Akt Thr (308) antibodies. Lower panels: quantitation of these blots after normalization with the β-Actin blot. (B) Upper panels: the expression and activation of PTEN detected by immunoblotting. Lower panels: quantitation of these blots after normalization with the β-Actin blot. (C) Upper panels: expression and activation of MAPK detected by immunoblotting. Lower panels: quantitation of these blots after normalization with the β-Actin blot. (D) The migration ability of 4T1 cells was enhanced by LY294002. (E) The invasion ability of 4T1 cells was enhanced by LY294002. *P < 0.05, **P < 0.01. p-MAPK, phosphor-MAPK Thr202/Tyr204; MAPK, mitogen-activated protein kinase; p-PTEN, phosphor-PTEN Ser380/Thr382/383; PTEN, phosphatase and tensin homolog; PI3K, phosphoinositide-3 kinase.